Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–161 of 161 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Injections, Intravenous Clear all

Conditions: Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions: BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: HIV Infections
Interventions: CD4-IgG, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Worcester, Massachusetts

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Oakland, California • Chicago, Illinois • Brooklyn, New York + 2 more

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 13 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 4
States / cities: Los Angeles, California • Oakland, California • Houston, Texas

Conditions: Aspergillosis
Interventions: Anidulafungin, VER002; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: Morris Plains, New Jersey

Conditions: Pain
Interventions: lidocaine, Placebo; Drug
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glioma
Interventions: RTA 744, RTA 744 injection; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 4
States / cities: Los Angeles, California • Dallas, Texas • Houston, Texas

Conditions: HIV Prevention, HCV, Opioid Use, Intravenous Drug Usage
Interventions: ARTAS Adapted Patient Navigation, Adherence Counseling; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 446 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Miami, Florida • New York, New York

Conditions: Herpes Simplex, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Crohn's Disease
Interventions: ABBV-154, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 45
States / cities: Dothan, Alabama • Mobile, Alabama • Coronado, California + 38 more

Conditions: Sarcoma, Soft Tissue
Interventions: BLZ-100; Drug
Lead sponsor: Blaze Bioscience Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colorectal Cancer
Interventions: DHA-paclitaxel; Drug
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 6
States / cities: Tucson, Arizona • Washington D.C., District of Columbia • Chicago, Illinois + 3 more

Conditions: Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Chandler, Arizona • Los Alamitos, California • Colorado Springs, Colorado + 16 more

Conditions: Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer
Interventions: Fluciclatide Injection; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: HIV Infections
Interventions: CD4 Antigens; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies

Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Integrated HIV Prevention and HCV Care for PWID

An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive